Kelly L. Harris Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Staff Fellow
staff
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Kelly L. Harris is a Staff Fellow at the National Center for Toxicological Research. Her research focuses on the molecular mechanisms of carcinogenesis, particularly the effects of environmental agents on DNA and gene expression. Harris has investigated the impact of benzo(a)pyrene on human colon cancer cells, examining cytotoxicity, proliferation, and DNA damage.
Her work also includes the development and application of methods for measuring cancer driver mutations. This includes studies using the CarcSeq approach to assess mutations in rat mammary and mouse lung cancer models, correlating these findings with incidence rates and strain/sex-specific variations. Collaborations within the National Center for Toxicological Research include work with Barbara L. Parsons, Binsheng Gong, Jennifer Faske, and Meagan B. Myers, with whom she has co-authored multiple publications. Harris has an h-index of 11 and has published 45 papers, accumulating 952 citations.
Metrics
- h-index: 11
- Publications: 45
- Citations: 952
Selected Publications
-
Abstract C054: Pharmacogenomics evaluation of histone deacetylase inhibitors on the treatment of triple-negative breast cancer subtypes (2025)
-
Tissue and Sex‐Specific Performance of a Cancer Driver Based Biomarker in <scp>rasH2</scp> ‐Tg Mice (2025)
-
Repeat treatment of organotypic airway cultures with ethyl methanesulfonate causes accumulation of somatic cell mutations without expansion of bronchial-carcinoma-specific cancer driver mutations (2024)
-
Abstract 2440: Cancer driver mutations as quantitative biomarkers of cancer risk interspecies analyses using CarcSeq (2024)
-
Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia (2021)
Collaboration Network
Top Collaborators
- CarcSeq Measurement of Rat Mammary Cancer Driver Mutations and Relation to Spontaneous Mammary Neoplasia
- Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia
- Repeat treatment of organotypic airway cultures with ethyl methanesulfonate causes accumulation of somatic cell mutations without expansion of bronchial-carcinoma-specific cancer driver mutations
- Abstract 2440: Cancer driver mutations as quantitative biomarkers of cancer risk interspecies analyses using CarcSeq
- Tissue and Sex‐Specific Performance of a Cancer Driver Based Biomarker in <scp>rasH2</scp> ‐Tg Mice
- CarcSeq Measurement of Rat Mammary Cancer Driver Mutations and Relation to Spontaneous Mammary Neoplasia
- Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia
- Abstract 2440: Cancer driver mutations as quantitative biomarkers of cancer risk interspecies analyses using CarcSeq
- Tissue and Sex‐Specific Performance of a Cancer Driver Based Biomarker in <scp>rasH2</scp> ‐Tg Mice
- CarcSeq Measurement of Rat Mammary Cancer Driver Mutations and Relation to Spontaneous Mammary Neoplasia
- Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia
- Abstract 2440: Cancer driver mutations as quantitative biomarkers of cancer risk interspecies analyses using CarcSeq
- Repeat treatment of organotypic airway cultures with ethyl methanesulfonate causes accumulation of somatic cell mutations without expansion of bronchial-carcinoma-specific cancer driver mutations
- Abstract 2440: Cancer driver mutations as quantitative biomarkers of cancer risk interspecies analyses using CarcSeq
- Tissue and Sex‐Specific Performance of a Cancer Driver Based Biomarker in <scp>rasH2</scp> ‐Tg Mice
- Benzo(a)pyrene-induced cytotoxicity, cell proliferation, DNA damage, and altered gene expression profiles in HT-29 human colon cancer cells
- Acceleration of benzo(a)pyrene-induced colon carcinogenesis by Western diet in a rat model of colon cancer
- CarcSeq Measurement of Rat Mammary Cancer Driver Mutations and Relation to Spontaneous Mammary Neoplasia
- Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia
- CarcSeq Measurement of Rat Mammary Cancer Driver Mutations and Relation to Spontaneous Mammary Neoplasia
- Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia
- Benzo(a)pyrene-induced cytotoxicity, cell proliferation, DNA damage, and altered gene expression profiles in HT-29 human colon cancer cells
- Benzo(a)pyrene-induced cytotoxicity, cell proliferation, DNA damage, and altered gene expression profiles in HT-29 human colon cancer cells
- Benzo(a)pyrene-induced cytotoxicity, cell proliferation, DNA damage, and altered gene expression profiles in HT-29 human colon cancer cells
- Abstract 3511: Varying Treatment outcomes of small molecule STING Agonist ADU-S100 in intratumoral and intravesical treatment regimens in syngeneic murine MB49 and in the N-methyl-N-nitrosourea (MNU) rat Model of urothelial carcinoma
- Abstract 3511: Varying Treatment outcomes of small molecule STING Agonist ADU-S100 in intratumoral and intravesical treatment regimens in syngeneic murine MB49 and in the N-methyl-N-nitrosourea (MNU) rat Model of urothelial carcinoma
- Abstract 3511: Varying Treatment outcomes of small molecule STING Agonist ADU-S100 in intratumoral and intravesical treatment regimens in syngeneic murine MB49 and in the N-methyl-N-nitrosourea (MNU) rat Model of urothelial carcinoma
- Abstract 3511: Varying Treatment outcomes of small molecule STING Agonist ADU-S100 in intratumoral and intravesical treatment regimens in syngeneic murine MB49 and in the N-methyl-N-nitrosourea (MNU) rat Model of urothelial carcinoma
- Abstract 3511: Varying Treatment outcomes of small molecule STING Agonist ADU-S100 in intratumoral and intravesical treatment regimens in syngeneic murine MB49 and in the N-methyl-N-nitrosourea (MNU) rat Model of urothelial carcinoma
Similar Researchers
Based on overlapping research topics